What Is Setipiprant and How Does It Differ from DHT Blockers Like Finasteride or Dutasteride?

Hair loss, particularly androgenetic alopecia, has long been associated with hormonal activity, inflammation, and genetic sensitivity of hair follicles. Over decades, treatments such as finasteride and dutasteride have targeted the hormonal pathway responsible for producing dihydrotestosterone, commonly known as DHT. More recently, researchers explored alternative biological pathways that might influence hair growth, including prostaglandin signaling. One of the most discussed experimental drugs in this area has been setipiprant. Understanding what setipiprant is and how it differs from DHT blockers requires a close look at hair biology, clinical research, and the limitations of current evidence.

The Biological Context of Hair Loss

Androgenetic alopecia occurs when hair follicles gradually shrink in response to hormonal signals, particularly DHT. DHT is a derivative of testosterone formed by an enzyme called 5-alpha-reductase. This hormone binds to receptors in genetically sensitive hair follicles, shortening the hair growth phase and producing progressively thinner hair until growth stops altogether. Hormones are not the only molecules involved in hair follicle regulation. Hair growth is also influenced by inflammatory mediators, immune signaling, blood flow, and local growth factors.

Among these signaling molecules are prostaglandins, which are lipid compounds involved in inflammation and tissue regulation. Prostaglandin D2, or PGD2, gained scientific attention after Garza and colleagues reported elevated levels in balding scalp tissue compared with non-balding areas. Their laboratory experiments indicated PGD2 might inhibit hair follicle growth by interacting with a receptor known as DP2.

This led to the hypothesis that blocking PGD2 activity might counteract that inhibition. Setipiprant was developed to target this specific receptor.

What Setipiprant Is and How It Works

Setipiprant is a selective antagonist of the prostaglandin D2 receptor DP2, also known as CRTh2 or GPR44. An antagonist is a compound that binds to a receptor and prevents its natural signaling molecule from activating it. By occupying the DP2 receptor, setipiprant was intended to block the inhibitory effects of PGD2 on hair follicles.

Setipiprant was originally investigated for allergic diseases such as asthma, because PGD2 plays a role in inflammatory immune responses. Its application in hair loss emerged after researchers connected PGD2 to suppressed hair growth in laboratory models. The reasoning behind setipiprant was not hormonal but based on inflammation-like signaling that influences the hair growth cycle. That makes it mechanistically different from existing hair loss drugs.

Setipiprant is not an approved medicine for hair loss in any country, and it is not available on prescription for that use. Material sold online under this name is unregulated, of unverified content, and has no established long-term safety record in people using it for hair.

How Finasteride and Dutasteride Work

Finasteride and dutasteride act by inhibiting the enzyme 5-alpha-reductase. This enzyme converts testosterone into DHT. When the enzyme is blocked, DHT levels in the scalp and bloodstream fall substantially.

Finasteride mainly inhibits type II 5-alpha-reductase, the form most active in hair follicles and the prostate. Dutasteride inhibits both type I and type II forms, which studies report produces a deeper reduction in DHT levels. By lowering DHT, these medications reduce the hormonal signal associated with follicle miniaturization. Trials report that this keeps hair follicles in the growth phase longer and, in some men, partially restores thickness.

Both are prescription-only medicines. Finasteride is approved for male pattern hair loss in many countries; dutasteride is approved for that use only in a few, such as South Korea and Japan, and is prescribed off-label for hair loss elsewhere.

Unlike setipiprant, which targets a signaling pathway related to inflammation and growth suppression, DHT blockers act on the hormonal mechanism that the evidence identifies as the main driver of androgenetic alopecia.

The Setipiprant Phase 2a Trial

The most relevant human study investigating setipiprant for androgenetic alopecia was a randomized, double-blind, placebo-controlled Phase 2a clinical trial in adult men with pattern hair loss (DuBois and colleagues, 2021). The study included 169 male participants between 18 and 49 years of age. Subjects received either oral setipiprant at a daily total of 2,000 milligrams — given as 1,000 mg twice a day — or a placebo, for 24 weeks. Hair growth was measured using standardized target-area hair counts, investigator global assessments, and participant self-assessments.

Despite the theoretical mechanism and encouraging laboratory results, the trial did not find statistically significant improvements in hair density or visible regrowth compared with placebo. The investigators reported setipiprant as generally well tolerated over the 24 weeks of the study, but it did not demonstrate meaningful effectiveness for hair loss. A 24-week tolerability finding says nothing about long-term safety.

This illustrates a recurring reality in medical research: biological plausibility does not always translate into clinical success. PGD2 does appear elevated in balding scalps, but blocking its receptor alone may not be enough to reverse follicle miniaturization.

Methodological Strengths and Limitations of the Setipiprant Trial

The trial used randomization, blinding, and placebo control, which reduce bias. Objective hair counts provided quantifiable outcomes rather than relying on subjective impressions alone.

Several limitations should be weighed. The duration of 24 weeks may not have been long enough to capture slower hair regrowth. The dose selected may not have achieved sufficient receptor blockade in scalp tissue. The study population was limited to relatively young men at specific stages of hair loss, which limits generalization. And hair loss is driven by multiple overlapping mechanisms, so blocking a single pathway may produce little clinical effect while hormonal signaling remains active.

Evidence Supporting DHT Blockers

Finasteride has been studied since the 1990s in large randomized controlled trials involving thousands of men. These studies reported reduced progression of hair loss and moderate regrowth in many participants. Long-term follow-up data indicate that continued use maintains hair density, and that stopping leads to renewed loss. Dutasteride, studied more recently, has been reported to suppress scalp DHT more strongly and, in some trials, to produce slightly higher hair counts than finasteride — though it is off-label for hair loss in most countries.

Evaluation in these studies used standardized photographs, hair counts, and patient-reported outcomes. Side effects including sexual dysfunction have been reported in a minority of users, and whether these can persist after stopping remains debated in the literature.

Both finasteride and dutasteride are contraindicated in women who are pregnant or who may become pregnant, because reducing DHT can affect the development of a male foetus. Broken or crushed tablets should not be handled by them; finasteride tablets are film-coated for that reason.

Setipiprant represents an attempt to influence hair growth by modifying prostaglandin signaling, a pathway related to inflammation and follicle growth regulation. Its aim was to remove an inhibitory signal that may suppress hair production.

Finasteride and dutasteride act on the hormonal trigger associated with follicle miniaturization in genetically predisposed individuals. They reduce the production of DHT, thereby lowering the primary stimulus for hair loss.

In practical terms, setipiprant sought to release a secondary brake on hair growth, while DHT blockers act on the main accelerator of hair loss.

What the Current Evidence Suggests

On the available clinical data, setipiprant has not shown meaningful benefit for androgenetic alopecia in humans. Its mechanism remains scientifically interesting, but the negative Phase 2a result substantially limits its prospects as a treatment. Finasteride and dutasteride, by contrast, are supported by decades of clinical research reporting measurable improvements in hair retention and regrowth.

This does not mean prostaglandin pathways are irrelevant to hair biology. It suggests that targeting PGD2 alone is not sufficient to overcome the hormonal drivers of hair loss.

Conclusion: Separating Laboratory Promise from Clinical Outcomes

When evaluating hair loss treatments, it is worth distinguishing between promising laboratory theories and reported clinical outcomes. Setipiprant offered a different approach by blocking prostaglandin signaling rather than hormones. The published human trial did not find significant hair regrowth. DHT blockers, while imperfect and associated with potential side effects, remain the pharmacological treatments with the strongest published evidence for androgenetic alopecia.

Setipiprant illustrates how complex hair loss biology is, and why targeting a single non-hormonal pathway may not be enough. For people seeking treatment today, the strongest published evidence continues to support therapies that reduce DHT activity.

Talk to a doctor or pharmacist before starting, stopping or combining finasteride, dutasteride or any other hair-loss treatment, and before taking any unapproved research compound such as setipiprant.

References (APA 7 Format)

Diamant, Z., Sidharta, P. N., Singh, D., O'Connor, B. J., Zuiker, R., & Leaker, B. R. (2014). Setipiprant, a selective CRTh2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clinical & Experimental Allergy, 44(8), 1044–1052. https://pubmed.ncbi.nlm.nih.gov/24964348/

DuBois, J., Bruce, S., Stewart, D., Kempers, S., et al. (2021). Setipiprant for androgenetic alopecia in males: Results from a randomized, double-blind, placebo-controlled phase 2a trial. Clinical, Cosmetic and Investigational Dermatology, 14, 1507–1517. https://pubmed.ncbi.nlm.nih.gov/34703265/

Kaufman, K. D., et al. (1998). Finasteride in the treatment of men with androgenetic alopecia. Journal of the American Academy of Dermatology, 39(4), 578–589. https://pubmed.ncbi.nlm.nih.gov/9777765/

Drake, L., Hordinsky, M., Fiedler, V., Swinehart, J., et al. (1999). The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. Journal of the American Academy of Dermatology, 41(4), 550–554. https://pubmed.ncbi.nlm.nih.gov/10495374/

Clark, R. V., Hermann, D. J., Cunningham, G. R., Wilson, T. H., et al. (2004). Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. Journal of Clinical Endocrinology & Metabolism, 89(5), 2179–2184. https://pubmed.ncbi.nlm.nih.gov/15126539/

Garza, L. A., Liu, Y., Yang, Z., Alagesan, B., et al. (2012). Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Science Translational Medicine, 4(126), 126ra34. https://pubmed.ncbi.nlm.nih.gov/22440736/